Using clinical trial data to tailor adjuvant treatments for individual patients.
The 2005 St. Gallen Consensus Panel provided recommendations for the treatment of early breast cancer which rely on target identification first. The foremost advance since 2005-demonstration of trastuzumab efficacy for patients with HER2-positive disease-was realized because an effective treatment was being evaluated and because the trial patients had the targeted disease as determined by quality-controlled assessment prior to study entry. The BIG 1-98 trial provides a striking reminder of patients' benefit from reliable pathological tumor assessment so that targeted therapies are effectively utilized. Several statistical methods facilitate use of clinical trial data for individualizing treatment. Subgroup analyses summarized using forest plots are essential for better understanding the disease and its treatment. The HERA trial illustrates the interpretation of relative and absolute treatment effects and estimating hazard rates over time as means to distinguish relevant differences across subgroups. Overview analyses, joint analyses, the STEPP (subpopulation treatment effect pattern plot) method and recursive partitioning are valuable tools.
Regan
Meredith M
MM
IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. mregan@jimmy.harvard.edu
Gelber
Richard D
RD
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects; D011960:Receptors, Estrogen / Q000187:drug effects; D011980:Receptors, Progesterone; D016019:Survival Analysis; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab
Ann Oncol. 2005 Oct;16(10):1569-83
16148022
J Clin Oncol. 1985 Oct;3(10):1418-31
4045529
N Engl J Med. 2006 Apr 20;354(16):1667-9
16625007
Breast Cancer Res. 2005;7(6):252-4
16280051
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
Biostatistics. 2004 Jul;5(3):465-81
15208206
Ann Oncol. 2006 Dec;17(12):1772-6
17071934
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
N Engl J Med. 2005 Oct 20;353(16):1659-72
16236737
J Clin Oncol. 2007 Sep 1;25(25):3846-52
17679725
Stat Med. 2000 Oct 15;19(19):2595-609
10986536
J Clin Oncol. 2007 Feb 10;25(5):486-92
17200148
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
J Clin Oncol. 1996 Oct;14(10):2738-46
8874335
Lancet. 2005 Apr 9-15;365(9467):1308
15823379
Breast. 2005 Dec;14(6):582-93
16199162
Lancet. 2007 Jan 6;369(9555):29-36
17208639
N Engl J Med. 2005 Dec 29;353(26):2747-57
16382061
JAMA. 2006 Apr 12;295(14):1658-67
16609087